406 related articles for article (PubMed ID: 18568671)
21. Reciprocal expression of Bcl-2 and p53 in breast ductal carcinoma.
Lee WY; Jin YT; Tzeng CC
Anticancer Res; 1996; 16(5A):3007-12. PubMed ID: 8917421
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
[TBL] [Abstract][Full Text] [Related]
23. [Comparative study of P 53, Bcl-2, and C-erbB-2 expression in low-grade papillary bladder tumors].
Ramos Soler D; Navarro Fos S; Villamón Fort R; Gil Salom M; Llombart Bosch A
Arch Esp Urol; 2003 Apr; 56(3):277-85. PubMed ID: 12768988
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
Temmim L; Baker H; Sinowatz F
Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
[TBL] [Abstract][Full Text] [Related]
25. Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation.
Shien T; Tashiro T; Omatsu M; Masuda T; Furuta K; Sato N; Akashi-Tanaka S; Uehara M; Iwamoto E; Kinoshita T; Fukutomi T; Tsuda H; Hasegawa T
J Clin Pathol; 2005 Dec; 58(12):1299-304. PubMed ID: 16311351
[TBL] [Abstract][Full Text] [Related]
26. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast.
Sharma BK; Ray A; Kaur S; Gupta S
Indian J Exp Biol; 1999 Mar; 37(3):223-7. PubMed ID: 10641149
[TBL] [Abstract][Full Text] [Related]
28. Tissue and serum c-erbB-2 and tissue EGFR in breast carcinoma: three years follow-up.
Mansour OA; Zekri AR; Harvey J; Teramoto Y; el-Ahmady O
Anticancer Res; 1997; 17(4B):3101-6. PubMed ID: 9329611
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Surgery; 2003 Feb; 133(2):219-21. PubMed ID: 12605184
[TBL] [Abstract][Full Text] [Related]
30. Proliferative activity (Ki-67), WT p53, Bcl-2 expression and their relationship to the tumor grade, in invasive ductal breast carcinomas.
Kalogeraki A; Garbagnati F; Santinami M; Zoras O
In Vivo; 2002; 16(2):141-4. PubMed ID: 12073773
[TBL] [Abstract][Full Text] [Related]
31. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of immunohistochemical staining for proliferating cell nuclear antigen, p53, and c-erbB-2 in sebaceous gland carcinoma and sweat gland carcinoma: comparison with histopathological parameter.
Hasebe T; Mukai K; Yamaguchi N; Ishihara K; Kaneko A; Takasaki Y; Shimosato Y
Mod Pathol; 1994 Jan; 7(1):37-43. PubMed ID: 7909154
[TBL] [Abstract][Full Text] [Related]
33. Breast infiltrating ductal carcinoma: analysis of hormone, HER-2 receptors and Ki-67 proliferation marker.
Mustać E; Zamolo G; Petković M; Dordević G; Radić J; Grgurević E; Batinac T
Coll Antropol; 2008 Sep; 32(3):741-6. PubMed ID: 18982746
[TBL] [Abstract][Full Text] [Related]
34. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
35. Relevance of the expression of bcl-2 in combination with p53 as a prognostic factor in breast cancer.
Jansen RL; Joosten-Achjanie SR; Volovics A; Arends JW; Hupperets PS; Hillen HF; Schouten HC
Anticancer Res; 1998; 18(6A):4455-62. PubMed ID: 9891509
[TBL] [Abstract][Full Text] [Related]
36. Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables.
Erdem O; Erdem M; Dursun A; Akyol G; Erdem A
Int J Gynecol Pathol; 2003 Jul; 22(3):254-60. PubMed ID: 12819392
[TBL] [Abstract][Full Text] [Related]
37. Expression of c-erbB-2 oncogene and p53 tumor suppressor gene in benign and malignant breast tissue: correlation with proliferative activity and prognostic index.
Alexiev BA; Bassarova AV; Popovska SL; Popov AA; Christov CZ
Gen Diagn Pathol; 1997 Jun; 142(5-6):271-9. PubMed ID: 9228249
[TBL] [Abstract][Full Text] [Related]
38. Bcl-2 protein expression and long-term survival in breast cancer.
Joensuu H; Pylkkänen L; Toikkanen S
Am J Pathol; 1994 Nov; 145(5):1191-8. PubMed ID: 7977649
[TBL] [Abstract][Full Text] [Related]
39. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
[TBL] [Abstract][Full Text] [Related]
40. beta-Catenin and p53 analyses of a breast carcinoma tissue microarray.
Chung GG; Zerkowski MP; Ocal IT; Dolled-Filhart M; Kang JY; Psyrri A; Camp RL; Rimm DL
Cancer; 2004 May; 100(10):2084-92. PubMed ID: 15139049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]